Skip to main content
. 2023 Jun 28;43(7):808–833. doi: 10.1002/cac2.12428

FIGURE 8.

FIGURE 8

Therapeutic potential of restoring MFN2 expression in ccRCC PDX mouse models. (A) Diagram of MFN2 overexpression recombinant lentivirus intratumorally injected into tumors of ccRCC PDX mice. (B‐D) Tumor image (B), tumor volume (C) and tumor weight (D) of ccRCC PDX tumors treated with MFN2 overexpression or control lentivirus (n = 4 per group). (E‐F) Representative IHC staining images (E) and statistical analysis (F) of Ki67 in ccRCC PDX tumors treated with MFN2 overexpression or control lentivirus. (G) Western blotting of EGFR pathway proteins in ccRCC PDX tumors treated with MFN2 overexpression or control lentivirus using the indicated antibodies. Data are presented as means ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001, by one‐way ANOVA (C) or Student's t test (D, F).

Abbreviations: PDX, Patient‐derived xenograft; oeCtrl, empty overexpression control; oeMFN2, overexpression of MFN2; p‐EGFR, phosphorylated epidermal growth factor receptor; p‐AKT, phosphorylated protein kinase B; p‐ERK1/2, phosphorylated extracellular signal‐regulated kinase 1/2.